AstraZeneca PLC Inks Antibiotics Deal With Department of Health and Human Services
The U.S. Department of Health and Human Services (HHS) said on Wednesday it signed a deal with British drugmaker AstraZeneca Plc to develop antibiotics.
The federal agency said it will share costs with AstraZeneca to develop a portfolio of drugs to treat illnesses caused by bioterrorism agents and antibiotic-resistant infections.
The Biomedical Advanced Research and Development Authority of the HHS will initially provide $50 million, and could pay up to $170 million for development of additional products as part of the deal, which is for five years.
Help employers find you! Check out all the jobs and post your resume.
The federal agency said it will share costs with AstraZeneca to develop a portfolio of drugs to treat illnesses caused by bioterrorism agents and antibiotic-resistant infections.
The Biomedical Advanced Research and Development Authority of the HHS will initially provide $50 million, and could pay up to $170 million for development of additional products as part of the deal, which is for five years.
Help employers find you! Check out all the jobs and post your resume.